Understanding Hypercortisolism and Its Impact on Cardiovascular Diseases - Episode 2
Clinical Presentation of Hypercortisolism
This episode explores how hypercortisolism extends beyond classic Cushingoid features, highlighting its variable presentation and role as a continuum of cortisol-driven cardiometabolic disease that is often underrecognized in clinical practice.
In this episode, ‘Clinical Presentation of Hypercortisolism,’ the expert faculty discuss the evolving understanding of hypercortisolism beyond its classic clinical presentation, emphasizing its variable manifestations and significant cardiometabolic impact. While traditional teaching has focused on recognizable Cushingoid features such as moon face, central obesity, and dorsocervical fat pads, the panelists highlight that many patients, particularly those with resistant hypertension or diabetes, do not exhibit these hallmark signs. This variability contributes to under recognition in clinical practice, especially among cardiologists who may not routinely consider hypercortisolism in patients without physical features.
The expert panel further explores how excess cortisol functions as a metabolic condition along a continuum, rather than a binary diagnosis. They discuss how varying levels of cortisol dysregulation can lead to a range of adverse outcomes, including hypertension, hyperglycemia, cardiovascular disease, atrial fibrillation, and bone loss. The faculty also note emerging evidence suggesting that cortisol contributes to insulin resistance, visceral fat accumulation, and muscle effects, reinforcing its broad systemic impact.
Importantly, the panelists underscore that individual responses to cortisol excess can differ widely, making hypercortisolism a highly heterogeneous condition. Overall, the discussion highlights the need for increased awareness of non-classic presentations and a greater appreciation of hypercortisolism as a clinically relevant contributor to cardiometabolic disease.
The next episode in this series, ‘Evolving Hypercortisolism Screening and Diagnosis,’ features the panelists discussing how emerging data are reshaping screening approaches for hypercortisolism, particularly in patients with resistant hypertension. The panel highlights a shift toward simpler diagnostic strategies and increased recognition of potentially reversible endocrine causes of cardiovascular disease.
